Skip to content
DataLookout
Menu

NCT06730672

An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date changed from estimate of Dec 30, 2024 to Dec 30, 2025 Show 5 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Interventions modified
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised at 1 of 2 sites
    • Study title revised
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date: Dec 10, 2024 to Dec 30, 2024
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Progression-free survival
Timeframe: From date of initiate treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months until disease progression or death

Secondary (5)

Overall survival
Objective response rate
Disease control rate
Duration of response
Dynamic changes in ctDNA levels and alterations in the ctDNA mutation profile

Arms and interventions

Volonib combined with Everolimus FormationExperimental

Volonib 200mg once daily and Everolimus 5mg once daily

Drugs: Vorolanib combined with Everolimus Formation

Sites

2 sites in 1 country